Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.79 |
| ▸ | GGT1 | P19440 | 1/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011618 | 0.88 | ALDH1A1 (1.00) | ALDH1A1GGT1POLBMEN1KMT2A | |
| SCHEMBL5404458 | 0.86 | POLB (1.00) | ALDH1A1GGT1POLBMEN1KMT2A | |
| SCHEMBL5393345 | 0.85 | ALDH1A1 (0.66) | ALDH1A1GGT1POLBMEN1KMT2A | |
| SCHEMBL5394947 | 0.81 | SMN1; SMN2 (1.00) | ALDH1A1MEN1KMT2ASMN1; SMN2PKM | |
| Glysobuzole SCHEMBL1815623 | 0.79 | ALDH1A1 (1.00) | ALDH1A1GGT1POLBMEN1KMT2A | |
| SCHEMBL3467612 | 0.78 | MEN1 (0.67) | ALDH1A1GGT1POLBMEN1KMT2A | |
| SCHEMBL5390639 | 0.78 | ALDH1A1 (0.73) | ALDH1A1GGT1POLBMEN1KMT2A | |
| SCHEMBL5396055 | 0.76 | ALDH1A1 (0.77) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL18077365 | 0.75 | ALDH1A1 (1.00) | ALDH1A1GGT1POLBMEN1KMT2A | |
| SCHEMBL3467266 | 0.75 | ALDH1A1 (0.62) | ALDH1A1GGT1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010073011-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2010-07-01 | — | — | WO | claimed |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2007-03-22 | — | — | US | claimed |
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | claimed |
| EP-1631558-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2006-03-08 | — | — | EP | claimed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | claimed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | claimed |
| WO-2010073011-A2 | COMPOUNDS USEFUL AS MEDICAMENTS | BETAGENON AB (SE) | 2010-07-01 | — | — | WO | disclosed |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2007-03-22 | — | — | US | disclosed |
| US-7173030-B2 | Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1631558-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | BIOVITRUM AB | 2005-01-13 | — | — | US | disclosed |
| WO-2004103980-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE I | BIOVITRUM AB (SE) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009821-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | ALDH1A1 53/4885GGT1 98/4885POLB 615/4885 |
| US-20070066614-A1 | Ihibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD17B11 | ALDH1A1 36/4885GGT1 168/4885POLB 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.